Aycan Zehra, Cetinkaya Ergun, Darendeliler Feyza, Vidinlisan Sadi, Bas Firdevs, Bideci Aysun, Demirel Fatma, Darcan Sukran, Buyukgebiz Atilla, Yildiz Metin, Berberoglu Merih, Bundak Ruveyde
Department of Paediatrics, Paediatric Endocrinology Unit, SB Ankara Diskapi Children's Hospital, Diskapi, Ankara, Turkey.
Clin Endocrinol (Oxf). 2008 May;68(5):769-72. doi: 10.1111/j.1365-2265.2007.03107.x. Epub 2007 Nov 2.
Patients with Turner syndrome (TS) are treated with GH to increase adult height. Although it is well established that GH promotes longitudinal bone growth, the effects of GH treatment on bone density are less clear.
To determine how GH treatment affects trabecular bone mineral density (BMD) in girls with TS at prepubertal ages in a prospective multicentre study.
Twenty-two patients with TS in the prepubertal period with a mean age of 9.8 +/- 2.5 (range 3.6-12.8) years were included in the study. All girls with TS underwent measurement of areal BMD using dual-energy X-ray absorptiometry (DXA) to obtain pretreatment anteroposterior (AP) lumbar spine values at L1-L4. Patients received GH (Genotropin) subcutaneously for 1 year at a dose of 0.05 mg/kg/day. Height and weight were measured at 3-monthly intervals. The AP lumbar spine areal BMD was remeasured using the same technique after 1 year of treatment. Lumbar spine BMD Z-scores and volumetric BMD (vBMD) Z-scores were calculated using national standards.
The height SDS of our cases showed a significant increase with GH therapy. The pretreatment lumbar spine (L1-L4) BMD Z-score was -1.2 +/- 1.2 SD and the vBMD Z-score was -0.8 +/- 1.6 SD. There were no significant changes in these values after 1 year of GH treatment. Prepubertal TS girls more than 11 years of age had lower vBMD Z-scores (-1.7 +/- 1.7 SD) than the girls aged less than 11 (-0.1 +/- 1.0 SD) (P < 0.05) at the onset of therapy. No significant changes were observed in these values after 1 year of GH therapy.
Osteopaenia becomes apparent in prepubertal TS patients as they reach pubertal age. BMD evaluation may be necessary in these prepubertal TS girls at diagnosis. Short-term GH therapy in these TS patients does not have a significant effect on bone density when measured at a site with a predominance of trabecular bone.
特纳综合征(TS)患者接受生长激素(GH)治疗以增加成年身高。虽然GH促进骨骼纵向生长已得到充分证实,但其对骨密度的影响尚不清楚。
在一项前瞻性多中心研究中,确定GH治疗对青春期前TS女童小梁骨矿物质密度(BMD)的影响。
本研究纳入了22例青春期前TS患者,平均年龄为9.8±2.5(范围3.6 - 12.8)岁。所有TS女童均采用双能X线吸收法(DXA)测量面积骨密度,以获取L1 - L4腰椎前后位(AP)的治疗前值。患者接受皮下注射GH(金磊赛增)1年,剂量为0.05 mg/kg/天。每3个月测量一次身高和体重。治疗1年后,采用相同技术重新测量腰椎AP面积骨密度。使用国家标准计算腰椎骨密度Z值和体积骨密度(vBMD)Z值。
我们的病例身高标准差积分(SDS)在GH治疗后显著增加。治疗前腰椎(L1 - L4)骨密度Z值为 - 1.2±1.2 SD,vBMD Z值为 - 0.8±1.6 SD。GH治疗1年后这些值无显著变化。治疗开始时,年龄超过11岁的青春期前TS女童的vBMD Z值( - 1.7±1.7 SD)低于11岁以下女童( - 0.1±1.0 SD)(P < 0.05)。GH治疗1年后这些值无显著变化。
青春期前TS患者在进入青春期时骨质疏松变得明显。对于这些青春期前TS女童,诊断时可能有必要进行骨密度评估。在这些TS患者中,当在以小梁骨为主的部位测量时,短期GH治疗对骨密度没有显著影响。